Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 22, 2009
Wed, January 21, 2009 Cobalis Corp. Enters into a Master Broker Agreement with MDC to Help Launch PreHistin into Global Markets
LAGUNA BEACH, Calif.--([ BUSINESS WIRE ])--Cobalis Corp. (Pink Sheets: CLSC), a pharmaceutical biotech company specializing in the development of anti-allergy medications, announced today that they have entered into a Master Broker agreement with Melodic Distribution Company (MDC). The goal of the agreement is to take advantage of MDC's strong international distribution channels and strategic partners.
MDC will seek international distribution for PreHistin™ within its vast network throughout Europe, Australia and Asia. MDC has received very strong indications of interest from its key distribution partners and will look to secure multiple distribution agreements in the near term.
Key members of MDC have worked previously with Cobalis to secure and manage the manufacturing of PreHistin for both FDA Phase III trials. The MDC team has extensive experience in manufacturing, distribution, marketing and branding of OTC nutritional supplements.
Steven Barnes, a managing partner of MDC and co-head of international distribution, said, "We are very pleased and excited to be a part of the international launch of PreHistin. We have been well aware of PreHistin's potential and efficacy through all of the anecdotal evidence we received from friends and family that have sampled the product over the years. This is a very unique product that completely differentiates itself from the current list of anti-histamines that dominate the marketplace."
Chas Radovich, the CEO of Cobalis, said, "We are very excited to have MDC represent us in the international distribution community. They are extremely well connected in all territories that Cobalis plans to penetrate. This will expedite our ability to launch PreHistin overseas and will coincide with our initial launch first quarter 2009 in the United States."
ABOUT COBALIS CORP. - PREHISTIN™
Headquartered in Laguna Beach, California, Cobalis Corp. is an over-the-counter pharmaceutical company. Its flagship product PreHistin™ is designed to prevent the primary causes of airborne allergies, and is set for launch first quarter 2009. The anti-allergy market is projected to exceed $10 Billion annually by 2010, and PreHistin™ is poised to capture significant market share. PreHistin™ is singularly positioned as it is the only Phase III clinically tested sublingual anti-allergy product with demonstrated efficacy.
PreHistin™, the "world's first pre-histamine," has shown in previous studies to modulate the body's level of protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin™ has essentially no risks or adverse effects to the general population including sedation and drowsiness found in most of the allergy products now available.
For more info please visit our website at [ www.Cobalis.com ].
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
